This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Study of Esomeprazole 20 mg or 40 mg vs Placebo Effectiveness on the Occurrence of Peptic Ulcers in Subjects on Low Dose Acetylsalicylic Acid (LDA) (Oberon)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00441727
First received: February 27, 2007
Last updated: July 12, 2012
Last verified: July 2012
Results First Received: August 28, 2009  
Study Type: Interventional
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor);   Primary Purpose: Prevention
Conditions: Gastric Ulcer
Duodenal Ulcer
Interventions: Drug: Esomeprazole 40 mg
Drug: Esomeprazole 20 mg
Drug: Placebo

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
The first subject was randomized 22 February 2007 and last subject completed 28 August 2008. Cardiologists, primary care physicians and gastroenterologists were the primary target investigators.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Esomeprazole 40 Esomeprazole 40 mg every day for 26 weeks in subjects on continuous low-dose ASA (acetylsalicyclic acid) (75-325 mg)
Esomeproazole 20 Esomeprazole 20 mg every day for 26 weeks in subjects on continuous low dose ASA (75-325 mg)
Placebo Placebo every day for 26 weeks in subjects on continuous low-dose ASA (75-325 mg)

Participant Flow:   Overall Study
    Esomeprazole 40   Esomeproazole 20   Placebo
STARTED   817 [1]   804 [1]   805 [1] 
COMPLETED   711 [1]   686 [1]   637 [1] 
NOT COMPLETED   106   118   168 
Protocol Violation                19                28                32 
Adverse Event                26                33                28 
Lack of Efficacy                7                8                48 
Withdrawal by Subject                40                34                47 
Lost to Follow-up                5                6                5 
Safety Reasons                3                1                3 
Various reason specified                6                8                5 
[1] ITT/randomised



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Esomeprazole 40 Esomeprazole 40 mg every day for 26 weeks in subjects on continuous low-dose ASA (acetylsalicyclic acid) (75-325 mg)
Esomeproazole 20 Esomeprazole 20 mg every day for 26 weeks in subjects on continuous low dose ASA (75-325 mg)
Placebo Placebo every day for 26 weeks in subjects on continuous low-dose ASA (75-325 mg)
Total Total of all reporting groups

Baseline Measures
   Esomeprazole 40   Esomeproazole 20   Placebo   Total 
Overall Participants Analyzed 
[Units: Participants]
 817   804   805   2426 
Age 
[Units: Participants]
       
<=18 years   0   0   0   0 
Between 18 and 65 years   240   246   260   746 
>=65 years   577   558   545   1680 
Gender 
[Units: Participants]
       
Female   380   375   402   1157 
Male   437   429   403   1269 


  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Percentage of Participants Who Experienced the Occurence of Peptic Ulcer(s).   [ Time Frame: During 26 weeks ]

2.  Secondary:   Percentage of Participants Who Experienced the Occurence of Gastric Ulcer.   [ Time Frame: During 26 weeks ]

3.  Secondary:   Percentage of Participants Who Experienced the Occurrence of Duodenal Ulcer.   [ Time Frame: During 26 weeks ]

4.  Secondary:   Number of Participants Reporting 0 in the Dichotomized RDQ (Reflux and Disease Questionnaire) Score (0 Versus >0) for the Dyspepsia Dimension During the 26-week Visit or the Week Prior to the Last Visit.   [ Time Frame: RDQ was assessed at baseline, 8 weeks, 16 week, 26 weeks or upon withdrawal. ]

5.  Secondary:   Number of Participants Reporting 0 in the Dichotomized RDQ (Reflux and Disease Questionnaire) Score (0 Versus >0) for the Gastroesophageal Reflux Disease Dimension During the 26-week Visit or the Week Prior to the Last Visit.   [ Time Frame: RDQ was assessed at baseline, 8 weeks, 16 week, 26 weeks or upon withdrawal. ]

6.  Secondary:   Number of Participants With Gastric and/or Duodenal Erosions.   [ Time Frame: The number of erosions was determined by endoscopy performed at baseline, 8 weeks and 26 weeks or upon withdrawal. ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
Not enough patients had peptic ulcer, gastric ulcer, or duodenal ulcer to report the intended primary endpoint of time to peptic ulcer and two secondary endpoints, time to gastric ulcer and time to duodenal ulcer. Percentage used instead.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.


Results Point of Contact:  
Name/Title: Gerard Lynch
Organization: AstraZeneca
e-mail: AZTrial_Results_Posting@astrazeneca.com


Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Responsible Party: AstraZeneca
ClinicalTrials.gov Identifier: NCT00441727     History of Changes
Other Study ID Numbers: D961FC00003
EudraCT No. 2006-005073-22
Study First Received: February 27, 2007
Results First Received: August 28, 2009
Last Updated: July 12, 2012